Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection.
Kidney recipients (n = 51) at risk of cytomegalovirus (CMV) disease, and requiring anti-lymphocyte globulin therapy because of biopsy-proven rejection, received high-dose ganciclovir, three times a week, for a total of nine doses. CMV disease was observed in seven (14%) patients within 6 months. Six of these patients were in a group of 45 CMV-seropositive recipients, and one was in a high-risk group of CMV-seronegative recipients. High-dose intravenous ganciclovir, three times a week, seems to be an efficient, safe and easy way to prevent CMV disease in patients treated with anti-lymphocyte globulins for acute rejection.
Dickenmann
Michael J
MJ
Division of Nephrology, Department of Internal Medicine, University Hospital, CH-4031 Basel, Switzerland. mdickenmann@uhbs.ch
Kabulbayev
Kairat
K
Steiger
Jürg
J
Cathomas
Gieri
G
Reusser
Pierre
P
Tamm
Michael
M
D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003587:Cytomegalovirus; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use*; D006084:Graft Rejection / Q000628:therapy*; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects*; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D000998:Antiviral Agents; D015774:Ganciclovir